Summary In a population-based series of 368 children undergoing surgery for medulloblastoma, 304 (83%) survived to complete a course of radiotherapy. Among those patients who completed radiotherapy, the shortterm survival rates were lower for young children (those aged under 5 years) than for older children, but by 6 years the survival rates were very similar (-35%) for children in both age groups. Higher survival rates were obtained in the young children where total macroscopic excision of the tumour was achieved. For older children there was no difference in survival rates between those with total or partial excision, though the survival rate was lower for those whose surgery was limited to biopsy. In young children radiotherapy dose had no effect on survival rates. In older children, survival rates were appreciably higher where doses had been at least 45Gy to the posterior fossa and 30Gy to the spinal cord, and there were also fewer spinal cord metastases among those who received a higher spinal cord dose. Ninety (30%) of the 304 children also received chemotherapy as part of their initially planned treatment; a wide variety of protocols was used and no conclusions could be drawn as to the effects on survival rates.
In the past, medulloblastoma has been generally regarded as having a very poor prognosis. The 3-year and 5-year survival rates for children diagnosed in Great Britain during 1962-70 were only 25% and 18% respectively (Draper et al., 1982) . Treatment during this period consisted of surgery, with varying degrees of removal of the tumour, followed by a course of radiotherapy; chemotherapy was sometimes used to treat recurrences. From 1970, at an increasing number of centres, children were also given chemotherapy as part of their initial treatment in addition to surgery and radiotherapy (Bloom, 1979; Marsden & Steward, 1976) , and clinical trials were set up to study the effect on survival of maintenance chemotherapy (Berry et al., 1981; Gerosa et al., 1981) . The purpose of the present analysis is to examine the possible effects on survival of variations in the initial planned treatment of childhood medulloblastoma. Table III and all other analyses presented here, these children are included in the "no chemotherapy" group. There was no significant difference between the age groups in the proportion of children receiving chemotherapy.
Survival
The overall five-year survival rate for the 368 surgically treated children in this series was 32%. The rate was 27% for those diagnosed during 1971-74 and 38% for 1975-77 . Table IV shows the proportions of children who survived to complete their radiotherapy, classified Figure 2 shows the survival curves for children aged under 5 years classified according to whether or not total macroscopic excision of their tumour was achieved. Survival rates in this age group were significantly higher for patients whose tumours were totally removed than for those who had residual tumour present after operation (X2 = 4.66 on 1 df, P < 0.05). There was no difference in survival among children aged 5-14 years between those whose tumours were totally removed and those whose tumours were only partially removed. The survival rate for children in this age group who underwent biopsy alone was significantly lower than for those who had more extensive surgery (X2=7.18 on 1 df, P<0.01). There was no corresponding effect of posterior fossa or spinal cord dose on survival rates in the younger age group. Because of the close correspondence between the doses of radiotherapy to the whole brain and to the spinal cord, it was not possible to analyse the effects of doses to these two fields independently. Table V summarises the results of significance tests on the survival curves for children in the two The neurosurgical centres were divided into 4 groups according to whether the total number of cases of childhood medulloblastoma treated by them during 1971-77 was in the range 1-5, 6-10, 11-20 or over 20. There was found to be no difference in survival rates between the four groups. The same classification was used for the radiotherapy centres, and again there was no difference in survival rates.
Discussion
The present series of children was ascertained from the national cancer registration scheme, which is notified of over 90% of all cases of childhood cancer in Great Britain (Draper et al., 1982) ; it is thus population based and nearly complete. The total number of 304 patients completing their initial planned course of radiotherapy is considerably larger than any previously reported in a detailed study of childhood medulloblastoma. There is known to be a risk of mortality for some years after diagnosis with this tumour; the minimum period of follow-up in our study is 5 years, with some patients having been followed up for as long as 12 years after diagnosis. The age distribution of this series was similar to that of a large series aggregated from a review of the literature (Choux et al., 1982) except that ours contained a larger number of children aged 10 years and over. This discrepancy may be explained by the fact that many of the series reviewed were from children's hospitals and would be expected to contain a preponderance of younger patients.
The post-operative treatment administered to individual children with medulloblastoma during 1971-77 was in general not randomly allocated within a clinical trial. However, a close examination of the data relating to children treated at particular centres suggests very strongly that at any centre at any given time the doses of radiotherapy were standardised, though with a tendency at some hospitals for older children to be given higher doses. It appears that at the great majority of hospitals at any time chemotherapy was either included in the initial planned treatment for all children with medulloblastoma or for none, or was randomly allocated within clinical trials. Therefore, although the analyses of survival related to treatment should be interpreted with some caution, it seems unlikely that differences in survival rates between groups of children undergoing different treatment are attributable to selective bias in the allocation of treatment to different categories of patient.
From the results presented above, it is clear that the short-term prognosis is poorer for children aged L-----------------under 5 years than for older children. However, in the longer term it appears that the survival rates for the two age groups are similar, and in the present series the 6-year survival rates for children who completed their treatment were 34% for those aged 0-4 years at diagnosis and 35% for those aged 5-14 years. Bloom et al. (1969) also found that long-term survival rates were similar for patients of all ages but that deaths tended to occur earlier among younger patients. The tendency for mortality to be more concentrated in a short period after diagnosis among younger patients has also been noted in children with neuroblastoma, another embryonal tumour of nervous tissue (Kinnier Wilson & Draper, 1974; Draper et al., 1982) .
In the past total excision of a medulloblastoma has generally been held to result in higher survival rates (Choux et al., 1982) . Among the children aged under 5 years in the present series, survival rates were considerably higher for those who had undergone total surgical removal of their tumours. In the older age group the extent of the surgery appeared to make little difference to survival rates, except that the survival rate for patients whose tumours were merely biopsied was lower. In 13/43 children whose surgery was limited to biopsy it was explicitly stated that the tumour was inoperable, and this presumably also applied in some other cases. Where excision of the tumour was attempted, many factors may have influenced the degree of removal, including tumour size and the extent of local spread. In particular no tumour involving the brain stem will have been totally removed. Brain stem involvement has been previously reported as an indicator of poor prognosis (Bloom et al., 1969) , and the 5-year survival rate in our series was indeed extremely low (1/13, 8%). However, it appears very likely that we failed to ascertain many cases of brain stem involvement; in our series 13/304 (4%) such cases were reported, whereas in a recent study of childhood medulloblastoma by the United Kingdom Children's Cancer Study Group, brain stem involvement was noted in 7/49 (14%) (C.C. Bailey, personal communication).
There was a clear advantage associated with a radiotherapy dose of at least 45 Gy to the posterior fossa in children aged 5 years and over, but higher doses apparently did not improve the prospects for survival for younger children. In a report on children aged under 5 years with brain tumours, Deutsch (1982) found very few survivors who received a dose of less than 40 Gy, but it is impossible to deduce the dose given to the patients with medulloblastoma in his series and for some patients the period of follow-up was very short. We found a tendency for higher doses to the posterior fossa to be associated with higher spinal cord doses, and this fact makes it difficult to determine the effect on survival of the spinal cord radiotherapy dose. Nevertheless when allowance was made for the effect of posterior fossa dose, the higher survival rate and lower incidence of spinal cord metastases amongst the older age group who received at least 30 Gy to the spinal cord both approached statistical significance.
There appeared to be little influence of chemotherapy on survival rates in our series but certain combinations of drugs may have a beneficial effect which it was not possible to detect in the present study because of the small number of children treated according to any one protocol. There is as yet no clear consensus amongst workers using standardised protocols on the effects of chemotherapy on survival in patients with medulloblastoma. Some studies have shown higher survival rates to be associated with chemotherapy, at least in some subgroups of patients (Berry et al., 1981; Bloom et al., 1969; Bloom, 1982a, b) , while in others there has so far been no demonstrable benefit derived from the use of chemotherapy (Evans et al., 1979; van Eys et al., 1981) .
In the great majority of children who completed their treatment for medulloblastoma and subsequently died, death was caused by the tumour, though a small number of exceptions has been identified. Two children, who had both undergone maintenance chemotherapy with BCNU, died with fibrosing changes in the lungs at 30 and 44 months after diagnosis, and were apparently tumour-free at the time of death. The fatal lung disease in these children was attributed to the use of BCNU (Bailey et al., 1978) and this drug has since been widely demonstrated to cause pulmonary fibrosis. One child died from progressive cerebral necrosis of unknown cause 39 months after the diagnosis of medulloblastoma, and was found to be tumour-free at post mortem. Another patient developed acute undifferentiated leukaemia and died 27 months after diagnosis of the original tumour. There were no other cases of second primary neoplasms in the present series. However, in a series of childhood medulloblastoma survivors treated in earlier years (1940 onwards) and with a correspondingly longer period of follow-up, cases of basal cell carcinoma, osteosarcoma, fibrosarcoma, meningioma and carcinoma of the colon have been observed (Kingston et al., in preparation) . In a study of 58 patients who died more than 5 years after treatment of childhood medulloblastoma during 1940-70, 48 (83%) deaths were directly attributable to the tumour, 5 were due to second primary neoplasms and 5 were due to other causes including infections and accidents (J.E. Kingston, personal communication). In the present series there have so far been 14 patients who died over five years after diagnosis, with recurrent tumour being the underlying cause of death in all cases.
In conclusion, the improvement in survival rates for childhood medulloblastoma during the period under review may be largely attributed to the effects of higher doses of radiotherapy on older children. Any definitive statement on the advantages of chemotherapy must await the analysis and publication of the several recent and current clinical trials for this tumour. The only factor which appeared to influence the prognosis for younger children was the extent of surgical removal of the tumour. With recent advances in neurosurgical techniques, the possibility that more extensive surgery may compensate for lower doses of radiotherapy could be explored in a prospective study. Effective treatment of childhood medulloblastoma may then be achieved without the long term complications associated with high doses of radiation.
